SS-31, also known as elamipretide, is a small peptide that works inside your mitochondria — the parts of your cells responsible for generating energy. Specifically, it binds to a molecule called cardiolipin on the inner mitochondrial membrane. Cardiolipin is essential for the electron transport chain that produces ATP, and when it gets damaged or disorganized — which happens steadily as we age and with oxidative stress — energy production in the cell drops significantly. SS-31 stabilizes it.
The energy production angle makes SS-31 relevant across almost every tissue in the body, but it has been most studied in the heart, kidneys, and skeletal muscle. In animal models, it dramatically reduces damage from ischemia-reperfusion injury — the cellular damage that occurs when blood flow is cut off and then restored, as happens during a heart attack or stroke. Human trials for heart failure with reduced ejection fraction are currently in Phase 2 and 3.
For people interested in longevity and cellular aging, the appeal is different. Declining mitochondrial function is one of the most well-established biological mechanisms of aging. Cells that can't produce energy efficiently begin to malfunction, accumulate damage, and eventually become senescent or die. SS-31 appears to interrupt this process by protecting the machinery at the heart of cellular energy production.
SS-31 is still experimental relative to more established peptides and most evidence comes from animal research and early human trials. It attracts interest from people specifically focused on longevity, mitochondrial health, and preventing the gradual cellular decline that drives aging. It requires injection and is typically used in cycles.
For educational and research purposes only. Never use any peptide or substance based on information found here — always consult a licensed healthcare professional before making any medical or health-related decision.
SS-31 was developed by Hazel Szeto and Peter Schiller at Weill Cornell Medical College. The peptide was designed specifically to target and protect the inner mitochondrial membrane — a difficult target to reach because drugs typically can't cross multiple membranes to get there. SS-31 solves this by being naturally drawn to the negatively charged inner membrane.
Animal studies have been extensive and highly consistent. In rodent models of heart failure, kidney injury, aging-related muscle loss, and ischemia-reperfusion injury, SS-31 has shown significant protective effects. Mitochondrial function improves, ATP production increases, and tissue damage decreases across every model tested.
Human trials are focused primarily on heart failure (conducted by Stealth BioTherapeutics, later Mitobridge). Phase 2 results in patients with heart failure showed improvements in exercise capacity and quality of life. Phase 3 trials have been conducted and results are being analyzed.
The longevity community uses SS-31 off-label, extrapolating from the animal and early human data. The core logic — that protecting mitochondria from age-related decline has broad benefits — is well-supported by decades of mitochondrial biology research, even if the specific outcomes of SS-31 use in healthy people are not yet documented.
this is early stage stuff and i knew that going in. mild side effects and some noticeable improvements in energy. hard to say how much is placebo but i feel better.
hard to measure objectively but i feel like recovery from hard sessions is faster. less of that lingering fatigue the day after. will continue.
i'm 61 and started this for energy and general aging stuff. six weeks in and my gym endurance is noticeably better. i can push harder before hitting the wall.
Epitalon is a synthetic tetrapeptide — four amino acids in sequence: Ala-Glu-Asp-Gly. It was developed by the…
GHK-Cu is a tiny copper-carrying protein fragment that occurs naturally in your blood, saliva, and urine. Your…
Matrixyl is the trade name for palmitoyl pentapeptide-4, a signal peptide developed specifically for skincare.…